Skip to main content

Table 1 Demographics and baseline characteristics

From: Clinical outcomes of empirical high-dose meropenem in critically ill patients with sepsis and septic shock: a randomized controlled trial

CharacteristicsStandard-dose meropenem (n = 38)High-dose meropenem (n = 38)P value
Age (years), mean (SD)67 (14.6)69 (19.0)0.657
Male, n (%)21 (55.3)19 (50)0.819
Weight (kg), mean (SD)56.4 (12.4)57.2 (14.7)0.797
Underlying disease, n (%)
 Diabetes13 (34.2)7 (18.4)0.192
 Hypertension17 (44.7)15 (39.5)0.817
 Heart failure5 (13.2)3 (7.9)0.711
 Chronic kidney disease5 (13.2)5 (13.2)1.000
 End stage renal disease6 (15.8)1 (2.6)0.108
 Chronic liver disease4 (10.5)3 (7.9)1.000
 COPD8 (21.1)2 (5.3)0.086
 Hematologic malignancy7 (18.4)8 (21.1)1.000
 Solid malignancy8 (21.1)7 (18.4)1.000
 Neutropenia4 (10.5)7 (18.4)0.516
 ARDS13 (34.2)10 (26.3)0.628
Cockroft-Gout ClCr (mL/min), median (IQR)41.81 (7.36–166.8)30.37 (7.04–141.75)0.377
Type of admission, n (%)
 ED17 (44.7)18 (47.4)1.000
 Ward21 (55.3)20 (52.6)
Mechanical ventilator, n (%)29 (76.3)27 (71.1)0.795
APACHE II score, mean (SD)18.8 (5.7)20 (6.3)0.395
mSOFA score, median (IQR)7 (0-13)8 (1-16)0.088
Septic shock, n (%)26 (68.4)27 (71.1)1.000
Source of infection
 Unknown, n (%)9 (23.7)6 (15.8)0.565
 Respiratory, n (%)15 (39.5)16 (42.1)1.000
 Urinary tract, n (%)2 (5.3)9 (23.7)0.047
 Bloodstream, n (%)12 (31.6)7 (18.4)0.289
 Multiple sources, n (%)5 (13.2)8 (21.2)0.540
Culture, n (%)21 (55.3)23 (60.5)0.817
 Polymicrobial6 (28.6)3 (13.0%)0.272
 Gram-positive pathogens5 (23.8)1 (4.3)0.088
 Gram-negative pathogens16 (76.2)20 (87.0)0.448
Escherichia coli7 (33.3)6 (26.1)0.744
Klebsiella pneumoniae8 (38.1)7 (30.4)0.752
Pseudomonas aeruginosa1 (4.8)6 (26.1)0.097
Acinetobacter baumannii1 (4.8)1 (4.3)1.000
  1. COPD chronic obstructive pulmonary disease, ARDS acute respiratory distress syndrome, ED emergency department, APACHE II Acute Physiology and Chronic Health Evaluation II, mSOFA modified Sequential Organ Failure Assessment